Trump’s COVID-19 treatment Regeneron gets FDA emergency use authorization

President Donald Trump shocked the entire world when he was diagnosed with COVID-19, only to emerge in what appeared to be a full recovery within a matter of days. The president credits his impressive recovery to not only his world-class doctors, but to the experimental drug Regeneron.

In what amounts to nothing less than a massive win for the president, according to the Daily Wire, the U.S. Food and Drug Administration announced on Saturday that Regeneron will now be eligible for emergency-use authorizations for thousands of Americans currently sick with COVID-19. 

The news of Regeneron’s approval comes in the wake of equally good news concerning the rapid and successful development of at least two COVID-19 vaccines.

What is Regeneron?

In simple terms, the experimental therapeutic drug — produced by Regeneron Pharmaceutical — is commonly known as an “antibody cocktail,” which when administered to a sick patient, works within the body to prevent COVID-19 from further infecting healthy cells.

The FDA has approved the drug for patients with moderate to severe cases of COVID-19, but added that it’s for patients who “are at high risk for progressing to severe COVID-19,” — presumably those with existing conditions that would statistically make them more susceptible to catching severe cases.

The main exception to the otherwise fantastic news is that Regeneron — at this stage — is not approved for patients who have already been admitted to the hospital for COVID-19 or who are on supplemental oxygen as a result of COVID-19 complications.

FDA Commissioner Dr. Stephen Hahn, according to the FDA website, added that Regeneron “may help outpatients avoid hospitalization and alleviate the burden on our health care system,” making it a potential game-changing tool for hospitals around the country.

What’s next?

Regeneron executives indicated several weeks ago that roughly 80,000 doses of the antibody cocktail would be available for patients by the end of November, with more on the way, saying that by the end of January the number will be at 300,000.

The timing couldn’t be better, as Pfizer and Moderna both made headlines last week with the announcement of their ultra-successful COVID-19 vaccines, which will begin to be fully distributed sometime in the spring of 2021.

According to KFF, COVID-19 vaccines could get clearance to be released as early as sometime in December.

Presumably, the early doses of the vaccine would be issued to the most at-risk people in need, such as frontline healthcare workers and first responders.

Though there is some uncertainty as to how former Vice President Joe Biden would handle the distribution of the vaccine should he take over the White House in January, it appears that for the first time during the entirety of 2020, there’s at least some hope that we’re coming to the end of this aggravating pandemic.

Share on facebook
Share to Facebook

Latest News